vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Industrial Logistics Properties Trust (ILPT). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $113.9M, roughly 1.6× Industrial Logistics Properties Trust). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -1.6%, a 14.9% gap on every dollar of revenue. On growth, Industrial Logistics Properties Trust posted the faster year-over-year revenue change (3.1% vs -1.8%). Industrial Logistics Properties Trust produced more free cash flow last quarter ($42.0M vs $24.6M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs 0.7%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Industrial Logistics Properties Trust is a real estate investment trust that owns and operates a portfolio of industrial and logistics real estate assets primarily across the United States. Its holdings include distribution centers, warehouses, and last-mile delivery properties, serving e-commerce, retail, manufacturing and supply chain operators to meet their storage and logistics operation needs.
AMPH vs ILPT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $113.9M |
| Net Profit | $24.4M | $-1.8M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | -22.1% |
| Net Margin | 13.3% | -1.6% |
| Revenue YoY | -1.8% | 3.1% |
| Net Profit YoY | -35.7% | 92.6% |
| EPS (diluted) | $0.51 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $113.9M | ||
| Q3 25 | $191.8M | $110.9M | ||
| Q2 25 | $174.4M | $112.1M | ||
| Q1 25 | $170.5M | $111.9M | ||
| Q4 24 | $186.5M | $110.5M | ||
| Q3 24 | $191.2M | $108.9M | ||
| Q2 24 | $182.4M | $110.6M | ||
| Q1 24 | $171.8M | $112.2M |
| Q4 25 | $24.4M | $-1.8M | ||
| Q3 25 | $17.4M | $-21.6M | ||
| Q2 25 | $31.0M | $-21.3M | ||
| Q1 25 | $25.3M | $-21.5M | ||
| Q4 24 | $38.0M | $-24.1M | ||
| Q3 24 | $40.4M | $-25.0M | ||
| Q2 24 | $37.9M | $-23.2M | ||
| Q1 24 | $43.2M | $-23.4M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | -22.1% | ||
| Q3 25 | 13.2% | -29.4% | ||
| Q2 25 | 24.2% | -30.8% | ||
| Q1 25 | 21.9% | -26.9% | ||
| Q4 24 | 24.2% | -31.1% | ||
| Q3 24 | 29.8% | -33.5% | ||
| Q2 24 | 30.3% | -32.4% | ||
| Q1 24 | 27.9% | -31.7% |
| Q4 25 | 13.3% | -1.6% | ||
| Q3 25 | 9.0% | -19.4% | ||
| Q2 25 | 17.8% | -19.0% | ||
| Q1 25 | 14.8% | -19.2% | ||
| Q4 24 | 20.4% | -21.8% | ||
| Q3 24 | 21.1% | -22.9% | ||
| Q2 24 | 20.8% | -20.9% | ||
| Q1 24 | 25.1% | -20.9% |
| Q4 25 | $0.51 | $-0.02 | ||
| Q3 25 | $0.37 | $-0.33 | ||
| Q2 25 | $0.64 | $-0.32 | ||
| Q1 25 | $0.51 | $-0.33 | ||
| Q4 24 | $0.74 | $-0.37 | ||
| Q3 24 | $0.78 | $-0.38 | ||
| Q2 24 | $0.73 | $-0.35 | ||
| Q1 24 | $0.81 | $-0.36 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $94.8M |
| Total DebtLower is stronger | $608.7M | $4.2B |
| Stockholders' EquityBook value | $788.8M | $489.7M |
| Total Assets | $1.6B | $5.2B |
| Debt / EquityLower = less leverage | 0.77× | 8.56× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $94.8M | ||
| Q3 25 | $276.2M | $83.2M | ||
| Q2 25 | $231.8M | $58.6M | ||
| Q1 25 | $236.9M | $108.0M | ||
| Q4 24 | $221.6M | $131.7M | ||
| Q3 24 | $250.5M | $153.9M | ||
| Q2 24 | $217.8M | $146.2M | ||
| Q1 24 | $289.6M | $128.4M |
| Q4 25 | $608.7M | $4.2B | ||
| Q3 25 | $608.6M | $4.2B | ||
| Q2 25 | $607.7M | $4.2B | ||
| Q1 25 | $603.9M | $4.3B | ||
| Q4 24 | $601.6M | $4.3B | ||
| Q3 24 | $596.4M | $4.3B | ||
| Q2 24 | $586.9M | $4.3B | ||
| Q1 24 | $594.0M | $4.3B |
| Q4 25 | $788.8M | $489.7M | ||
| Q3 25 | $776.7M | $494.1M | ||
| Q2 25 | $757.5M | $519.1M | ||
| Q1 25 | $751.3M | $539.5M | ||
| Q4 24 | $732.3M | $562.0M | ||
| Q3 24 | $727.7M | $585.9M | ||
| Q2 24 | $713.3M | $618.3M | ||
| Q1 24 | $672.4M | $643.2M |
| Q4 25 | $1.6B | $5.2B | ||
| Q3 25 | $1.7B | $5.2B | ||
| Q2 25 | $1.6B | $5.2B | ||
| Q1 25 | $1.6B | $5.4B | ||
| Q4 24 | $1.6B | $5.4B | ||
| Q3 24 | $1.5B | $5.5B | ||
| Q2 24 | $1.5B | $5.5B | ||
| Q1 24 | $1.6B | $5.5B |
| Q4 25 | 0.77× | 8.56× | ||
| Q3 25 | 0.78× | 8.49× | ||
| Q2 25 | 0.80× | 8.09× | ||
| Q1 25 | 0.80× | 7.96× | ||
| Q4 24 | 0.82× | 7.65× | ||
| Q3 24 | 0.82× | 7.35× | ||
| Q2 24 | 0.82× | 6.96× | ||
| Q1 24 | 0.88× | 6.70× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $60.7M |
| Free Cash FlowOCF − Capex | $24.6M | $42.0M |
| FCF MarginFCF / Revenue | 13.4% | 36.9% |
| Capex IntensityCapex / Revenue | 4.5% | 16.4% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $79.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $60.7M | ||
| Q3 25 | $52.6M | $22.7M | ||
| Q2 25 | $35.6M | $18.4M | ||
| Q1 25 | $35.1M | $11.4M | ||
| Q4 24 | $29.0M | $2.0M | ||
| Q3 24 | $60.0M | $-3.4M | ||
| Q2 24 | $69.1M | $10.8M | ||
| Q1 24 | $55.3M | $8.0M |
| Q4 25 | $24.6M | $42.0M | ||
| Q3 25 | $47.2M | $17.6M | ||
| Q2 25 | $25.0M | $15.2M | ||
| Q1 25 | $24.4M | $5.0M | ||
| Q4 24 | $16.6M | $-3.7M | ||
| Q3 24 | $46.2M | $-5.9M | ||
| Q2 24 | $63.1M | $9.4M | ||
| Q1 24 | $46.5M | $5.9M |
| Q4 25 | 13.4% | 36.9% | ||
| Q3 25 | 24.6% | 15.9% | ||
| Q2 25 | 14.3% | 13.5% | ||
| Q1 25 | 14.3% | 4.5% | ||
| Q4 24 | 8.9% | -3.4% | ||
| Q3 24 | 24.1% | -5.5% | ||
| Q2 24 | 34.6% | 8.5% | ||
| Q1 24 | 27.1% | 5.2% |
| Q4 25 | 4.5% | 16.4% | ||
| Q3 25 | 2.8% | 4.6% | ||
| Q2 25 | 6.1% | 2.9% | ||
| Q1 25 | 6.3% | 5.7% | ||
| Q4 24 | 6.7% | 5.2% | ||
| Q3 24 | 7.2% | 2.3% | ||
| Q2 24 | 3.3% | 1.3% | ||
| Q1 24 | 5.1% | 1.9% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
ILPT
Segment breakdown not available.
